Pharmaceutical Business review is using cookies

ContinueLearn More

Teva to commercialize Verinata Health’s verifi prenatal test in Israel

Teva Pharmaceutical has entered into an exclusive five-year agreement with Verinata Health, an Illumina company, to commercialize the verifi non-invasive prenatal test in Israel.

As per the terms of the agreement, Teva Pharmaceuticals will be an exclusive distributor of the verifi prenatal test in Israel, with all tests being carried out in Verinata Health’s CLIA-certified laboratory in California, US.

Teva Israel CEO Ron Mayron said, "The verifi prenatal test exemplifies our investment in the women’s health segment and our commitment to offer clinically-validated, innovative new products to Israeli women to improve their health and quality of life."

MOR Institute for Medical Data, which is a wholly-owned subsidiary of Clalit Health Services, has planned to provide verifi prenatal test for Clalit Health customers through Teva to prevent the high risk of fetus with a chromosomal abnormality.

The MOR Institute will also start a 9,000-patient clinical outcomes registry to collect the performance data and will share the data with Verinata.

Clalit Health Services will offer reimbursement for the verifi prenatal test through supplemental insurance.

Verinata Global Commercial Operations vice president Vance Vanier said, "With the test now available in several international markets, we look forward to expanding our commercial presence by continuing to partner with leading organizations around the globe."